RT Conference Proceedings
T1 Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
A1 Dang, C.
A1 Ewer, M. S.
A1 Delaloge, S.
A1 Ferrero, J-M.
A1 Colomer, R.
A1 de la Cruz Merino, L.
A1 Dadswell, K.
A1 Verrill, M.
A1 Eiger, D.
A1 Sarkar, S.
A1 de Haas, S.
A1 Restuccia, E.
A1 Swain, S. M.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-05-08
LK https://hdl.handle.net/10668/27618
UL https://hdl.handle.net/10668/27618
LA en
DS RISalud
RD Apr 12, 2025